Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision

Joaquim Mullol | Aziz Sheikh | Yuan Zhang | Wojtek Wiercioch | Holger J. Schünemann | Matthew Ventresca | Dermot Ryan | Antonio Valero | Ioana Agache | Claus Bachert | Thomas Casale | Ludger Klimek | Piotr Kuna | Nikolaos Papadopoulos | Arunas Valiulis | Erkka Valovirta | Magnus Wickman | Torsten Zuberbier | Luo Zhang | Niels H. Chavannes | Arnav Agarwal | Ivan D. Florez | Ken Ohta | Behnam Sadeghirad | Antonella Muraro | Gianni Passalacqua | Dana Wallace | Susan Waserman | Mihaela Zidarn | A. Sheikh | H. Schünemann | J. Bousquet | T. Zuberbier | C. Bachert | J. Brożek | T. Casale | P. Demoly | K. Ohta | Á. Cruz | N. Chavannes | W. Fokkens | J. Fonseca | J. Mullol | R. O’Hehir | N. Papadopoulos | G. Passalacqua | R. Pawankar | D. Ryan | B. Samoliński | E. Valovirta | I. Agache | P. Kuna | E. Meltzer | D. Price | M. Wickman | D. Larenas-Linnemann | A. Muraro | A. Agarwal | S. Bosnic-Anticevich | L. Klimek | A. Valiulis | P. Hellings | P. Panzner | P. Schmid‐Grendelmeier | Luo Zhang | B. Sadeghirad | R. Brignardello-Petersen | W. Wiercioch | I. Etxeandia-Ikobaltzeta | Y. Zhang | C. Cuello-Garcia | J. Riva | Y. Roldán | S. Waserman | Hae‐Sim Park | J. Yepes-Nuñez | Jean Bousquet | D. Wallace | Pascal Demoly | W. Canonica | I. Flórez | A. Togias | M. Zidarn | Ruby Pawankar | M. Dykewicz | Sergio Kowalski | Alkis Togias | Peter Schmid‐Grendelmeier | Joao Fonseca | Jan L. Brożek | Sinthia Bosnic‐Anticevich | Romina Brignardello‐Petersen | Walter G. Canonica | Jaime Correia de Sousa | Alvaro A. Cruz | Carlos A. Cuello‐Garcia | Mark Dykewicz | Itziar Etxeandia‐Ikobaltzeta | Wytske Fokkens | Peter W. Hellings | Kaja‐Triin Laisaar | Désirée E. Larenas‐Linnemann | Karin C. L&phgr;drup Carlsen | Peter J. Manning | Eli Meltzer | Robyn O'Hehir | Petr Panzner | Hae‐Sim Park | David Price | John J. Riva | Yetiani Roldán | Boleslaw Samolinski | Juan José Yepes‐Nuñez | J. C. de Sousa | S. Kowalski | K. Laisaar | M. Ventresca | P. Manning | A. Valero | R. O'Hehir | A. Sheikh | J. Bousquet | S. Bosnic‐Anticevich

[1]  T. Harr,et al.  [Allergology and clinical immunology]. , 2018, Revue medicale suisse.

[2]  C. Wang,et al.  [An introduction to Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision]. , 2011, Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery.

[3]  F. Spertini,et al.  [Seasonal allergic rhinitis]. , 2018, Revue medicale suisse.

[4]  G. Guyatt,et al.  [GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines]. , 2018, Gaceta sanitaria.

[5]  H. Schünemann,et al.  [GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction.] , 2017, Recenti progressi in medicina.

[6]  A. Ghoshal,et al.  Burden of Respiratory Disease in Korea: An Observational Study on Allergic Rhinitis, Asthma, COPD, and Rhinosinusitis , 2016, Allergy, asthma & immunology research.

[7]  Elie A Akl,et al.  GRADE Guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health. , 2016, Journal of clinical epidemiology.

[8]  Todor A Popov,et al.  MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. , 2016, The Journal of allergy and clinical immunology.

[9]  D. Postma,et al.  Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5) , 2016, Clinical and Translational Allergy.

[10]  A. Ghoshal,et al.  Burden of respiratory disease in Thailand: Results from the APBORD observational study , 2016, Medicine.

[11]  J. Bousquet,et al.  AIRWAYS-ICPs (European Innovation Partnership on Active and Healthy Ageing) from concept to implementation , 2016, European Respiratory Journal.

[12]  A. Bohnen,et al.  Atopic dermatitis, asthma and allergic rhinitis in general practice and the open population: a systematic review , 2016, Scandinavian journal of primary health care.

[13]  L. Cardell,et al.  TOTALL: high cost of allergic rhinitis—a national Swedish population-based questionnaire study , 2016, npj Primary Care Respiratory Medicine.

[14]  A. Ghoshal,et al.  Burden of respiratory disease in Thailand: Results from the APBORD observational study. , 2016, Medicine.

[15]  E. Akl,et al.  The GRADE evidence-to-decision framework: a report of its testing and application in 15 international guideline panels , 2015, Implementation Science.

[16]  F. Rodenas,et al.  MACVIA‐ARIA Sentinel NetworK for allergic rhinitis (MASK‐rhinitis): the new generation guideline implementation , 2015, Allergy.

[17]  J. Bousquet,et al.  Portugal at the cross road of international chronic respiratory programmes. , 2015, Revista portuguesa de pneumologia.

[18]  S. Miller,et al.  The improved efficacy of a fixed‐dose combination of fluticasone furoate and levocabastine relative to the individual components in the treatment of allergic rhinitis , 2015, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[19]  Chang-Hoon Kim,et al.  Comparison of Intranasal Ciclesonide, Oral Levocetirizine, and Combination Treatment for Allergic Rhinitis , 2014, Allergy, asthma & immunology research.

[20]  J. Bousquet,et al.  MASK-rhinitis, a single tool for integrated care pathways in allergic rhinitis. , 2015, World hospitals and health services : the official journal of the International Hospital Federation.

[21]  E. Vicaut,et al.  The minimally important difference in the Rhinoconjunctivitis Total Symptom Score in grass‐pollen‐induced allergic rhinoconjunctivitis , 2014, Allergy.

[22]  S. Simoens,et al.  Economic burden of inadequate management of allergic diseases in the European Union: a GA2LEN review , 2014, Allergy.

[23]  J. Bousquet,et al.  Prevalence of asthma and its association with rhinitis in the elderly. , 2014, Respiratory medicine.

[24]  D. Postma,et al.  Integrated care pathways for airway diseases (AIRWAYS-ICPs) , 2014, European Respiratory Journal.

[25]  D. Price,et al.  Long-term, randomized safety study of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) in subjects with chronic rhinitis. , 2014, The journal of allergy and clinical immunology. In practice.

[26]  H. Schünemann,et al.  Methodological rigor and reporting of clinical practice guidelines in patients with allergic rhinitis: QuGAR study. , 2014, The Journal of allergy and clinical immunology.

[27]  H. Vliagoftis,et al.  Association between allergic rhinitis and asthma in a Northern Alberta cohort , 2013, Journal of Otolaryngology - Head & Neck Surgery.

[28]  J. Virchow,et al.  Clinically Relevant Effect of a New Intranasal Therapy (MP29-02) in Allergic Rhinitis Assessed by Responder Analysis , 2013, International Archives of Allergy and Immunology.

[29]  J. Bousquet,et al.  A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis. , 2013, Journal of investigational allergology & clinical immunology.

[30]  H. Korkmaz,et al.  The Effect of Combined Medical Treatment on Quality of Life in Persistent Allergic Rhinitis , 2013, Indian Journal of Otolaryngology and Head & Neck Surgery.

[31]  E. Meltzer,et al.  MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safety. , 2012, Allergy and asthma proceedings.

[32]  J. Bousquet,et al.  Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray. , 2012, British journal of clinical pharmacology.

[33]  P. Hellings,et al.  Explorative study on patient’s perceived knowledge level, expectations, preferences and fear of side effects for treatment for allergic rhinitis , 2012, Clinical and Translational Allergy.

[34]  J. Bousquet,et al.  A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. , 2012, The Journal of allergy and clinical immunology.

[35]  C. Cingi,et al.  Prevalence and diversity of allergic rhinitis in regions of the world beyond Europe and North America , 2012, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[36]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[37]  C. Fairchild,et al.  Outcomes and Cost Comparison of Three Therapeutic Approaches to Allergic Rhinitis , 2011, American journal of rhinology & allergy.

[38]  Howard Balshem,et al.  GRADE guidelines: 3. Rating the quality of evidence. , 2011, Journal of clinical epidemiology.

[39]  H. Schünemann,et al.  How representative are clinical study patients with allergic rhinitis in primary care? , 2011, The Journal of allergy and clinical immunology.

[40]  G. Guyatt,et al.  GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. , 2011, Journal of clinical epidemiology.

[41]  Gordon H Guyatt,et al.  GRADE guidelines: 2. Framing the question and deciding on important outcomes. , 2011, Journal of clinical epidemiology.

[42]  H. Schünemann.  Guidelines 2.0: Do No Net Harm—The Future of Practice Guideline Development in Asthma and Other Diseases , 2011, Current allergy and asthma reports.

[43]  C. Bias.  The Cochrane Collaboration's tool for assessing risk of bias in randomised trials , 2011 .

[44]  V. Modgill,et al.  Efficacy and safety of montelukast add-on therapy in allergic rhinitis. , 2010, Methods and findings in experimental and clinical pharmacology.

[45]  Holger J Schünemann,et al.  Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. , 2010, The Journal of allergy and clinical immunology.

[46]  F. Hampel,et al.  Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. , 2010, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[47]  Michele Tarsilla.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, Journal of MultiDisciplinary Evaluation.

[48]  M. Rottem.  [Allergic rhinitis and its impact on asthma]. , 2010, Harefuah.

[49]  J. Bousquet,et al.  Risk of first‐generation H1‐antihistamines: a GA2LEN position paper , 2010, Allergy.

[50]  C. Cingi,et al.  Nasal steroid perspective: knowledge and attitudes , 2010, European Archives of Oto-Rhino-Laryngology.

[51]  M. Malice,et al.  Clinical Studies of Combination Montelukast and Loratadine in Patients with Seasonal Allergic Rhinitis , 2009, The Journal of asthma : official journal of the Association for the Care of Asthma.

[52]  M. Jhaveri,et al.  Cost and resource utilization comparisons of second-generation antihistamines vs. montelukast for allergic rhinitis treatment. , 2009, Allergy and asthma proceedings.

[53]  J. Bousquet,et al.  Unmet needs in severe chronic upper airway disease (SCUAD). , 2009, The Journal of allergy and clinical immunology.

[54]  S. Spector,et al.  Comparison of olopatadine 0.6% nasal spray versus fluticasone propionate 50 microg in the treatment of seasonal allergic rhinitis. , 2009, Allergy and asthma proceedings.

[55]  T. Fukuda,et al.  Effects of pranlukast hydrate on airway hyperresponsiveness in non-asthmatic patients with Japanese cedar pollinosis. , 2009, Allergology international : official journal of the Japanese Society of Allergology.

[56]  J. Liang,et al.  [Clinical research of Ibudilast on treating the steroid resistant allergic rhinitis]. , 2009, Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery.

[57]  I. Okubo,et al.  Utility weights for allergic rhinitis based on a community survey with a time trade-off technique in Japan. , 2009, Allergology international : official journal of the Japanese Society of Allergology.

[58]  M. Jhaveri,et al.  Cost-effectiveness of second-generation antihistamines and montelukast in relieving allergic rhinitis nasal symptoms. , 2008, American health & drug benefits.

[59]  S. Spector,et al.  The diagnosis and management of rhinitis: an updated practice parameter. , 2008, The Journal of allergy and clinical immunology.

[60]  Anand A. Dalal,et al.  Economic burden of rhinitis in managed care: a retrospective claims data analysis. , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[61]  G. Viegi,et al.  Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 * , 2008, Allergy.

[62]  F. Hampel,et al.  Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis. , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[63]  P. Górski,et al.  Quality of life in patients with persistent allergic rhinitis treated with montelukast alone or in combination with levocetirizine or desloratadine. , 2008, Journal of investigational allergology & clinical immunology.

[64]  Ching-Ting Tan,et al.  Comparison of Antileukotrienes and Antihistamines in the Treatment of Allergic Rhinitis , 2007, American journal of rhinology.

[65]  T. Reiss,et al.  Efficacy of montelukast for treating perennial allergic rhinitis. , 2007, Allergy and asthma proceedings.

[66]  P. Górski,et al.  Montelukast with desloratadine or levocetirizine for the treatment of persistent allergic rhinitis. , 2006, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[67]  E. Meltzer,et al.  Impact of azelastine nasal spray on symptoms and quality of life compared with cetirizine oral tablets in patients with seasonal allergic rhinitis. , 2006, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[68]  D. Strachan,et al.  Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys , 2006, The Lancet.

[69]  D. Can,et al.  Is the usage of intranasal glucocorticosteroids alone in allergic rhinitis sufficient? , 2006, Allergy and asthma proceedings.

[70]  B. Lipworth,et al.  Effects of levocetirizine as add‐on therapy to fluticasone in seasonal allergic rhinitis , 2006, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[71]  R. Jiang.  Efficacy of a leukotriene receptor antagonist in the treatment of perennial allergic rhinitis. , 2006, The Journal of otolaryngology.

[72]  Y. Harabuchi,et al.  Evaluation of Patient Satisfaction with Treatment for Birch Pollinosis , 2006 .

[73]  D. Revicki,et al.  Rhinitis Symptom Utility Index (RSUI) in Chinese Subjects: A Multiattribute Patient-preference Approach , 2006, Quality of Life Research.

[74]  C. Bachert,et al.  Efficacy, cost-effectiveness, and tolerability of mometasone furoate, levocabastine, and disodium cromoglycate nasal sprays in the treatment of seasonal allergic rhinitis. , 2005, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[75]  G. Viegi,et al.  Rhinitis is an independent risk factor for developing cough apart from colds among adults , 2005, Allergy.

[76]  G. Guyatt,et al.  Measurement Properties and Interpretability of the Chronic Respiratory Disease Questionnaire (CRQ) , 2005, COPD.

[77]  B. Lange.  Wirksamkeit, Kosten-Wirksamkeit und Verträglichkeit topischer intranasaler Arzneimittel zur Behandlung der allergischen Rhinitis. Systematische Review mit Metaanalysen (Teil A) und klinische Studie (Teil B) , 2005 .

[78]  P. Godard,et al.  A multicenter clinical study of the efficacy and tolerability of azelastine nasal spray in the treatment of seasonal allergic rhinitis: a comparison with oral cetirizine , 2005, European Archives of Oto-Rhino-Laryngology.

[79]  K. Lue,et al.  A Comparison of Cetirizine and Montelukast for Treating Childhood Perennial Allergic Rhinitis , 2004 .

[80]  P. Kuna,et al.  Montelukast plus cetirizine in the prophylactic treatment of seasonal allergic rhinitis: influence on clinical symptoms and nasal allergic inflammation , 2004, Allergy.

[81]  N. Martinelli,et al.  Randomized placebo‐controlled trial comparing fluticasone aqueous nasal spray in mono‐therapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[82]  Todd A. Lee,et al.  Evaluating the efficiency of treatment in the allergic rhinitis market. , 2004, Journal of managed care pharmacy : JMCP.

[83]  S. Garnham,et al.  A placebo controlled study comparing the efficacy of intranasal azelastine and beclomethasone in the treatment of seasonal allergic rhinitis , 2004, European Archives of Oto-Rhino-Laryngology.

[84]  E. Meltzer,et al.  Montelukast improves symptoms of seasonal allergic rhinitis over a 4‐week treatment period , 2003, Allergy.

[85]  J Bousquet,et al.  Implementation of guidelines for seasonal allergic rhinitis: a randomized controlled trial , 2003, Allergy.

[86]  W. Berger,et al.  Efficacy of azelastine nasal spray in patients with an unsatisfactory response to loratadine. , 2003, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[87]  P. Gibson,et al.  Intranasal corticosteroids for asthma control in people with coexisting asthma and rhinitis. , 2003, The Cochrane database of systematic reviews.

[88]  M. Malice,et al.  Randomized controlled trial evaluating the clinical benefit of montelukast for treating spring seasonal allergic rhinitis. , 2003, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[89]  M. Dykewicz.  7. Rhinitis and sinusitis. , 2003, The Journal of allergy and clinical immunology.

[90]  Shelby D Reed,et al.  Direct costs of allergic rhinitis in the United States: estimates from the 1996 Medical Expenditure Panel Survey. , 2003, The Journal of allergy and clinical immunology.

[91]  D. Wang,et al.  Patient Preference and Sensory Perception of Three Intranasal Corticosteroids for Allergic Rhinitis , 2003, Clinical drug investigation.

[92]  G. Rodrigo,et al.  Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. , 2002, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[93]  M. Malice,et al.  Montelukast for treating seasonal allergic rhinitis: a randomized, double‐blind, placebo‐controlled trial performed in the spring , 2002, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[94]  M. Malice,et al.  Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. , 2002, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[95]  B. Tarchalska-Kryńska,et al.  Treatment of allergic rhinitis , 1994, Australian family physician.

[96]  P. Cauwenberge,et al.  Consensus statement on the treatment of allergic rhinitis (European Academy of Allergology and Clinical Immunology) , 2001 .

[97]  L. Palmer,et al.  Asthma, rhinitis, and skin test reactivity to aeroallergens in families of asthmatic subjects in Anqing, China. , 2001, American journal of respiratory and critical care medicine.

[98]  M. Kaliner.  Patient preferences and satisfaction with prescribed nasal steroids for allergic rhinitis. , 2001, Allergy and asthma proceedings.

[99]  T. Craig,et al.  Efficacy of a steroid nasal spray compared with an antihistamine nasal spray in the treatment of perennial allergic rhinitis , 2000, The Journal of the American Osteopathic Association.

[100]  E. Meltzer,et al.  Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. , 2000, The Journal of allergy and clinical immunology.

[101]  D C Schutt,et al.  The cost of productivity losses associated with allergic rhinitis. , 2000, The American journal of managed care.

[102]  J Bousquet,et al.  Consensus statement * on the treatment of allergic rhinitis , 2000, Allergy.

[103]  Drago,et al.  Comparison of the effects of fluticasone propionate, aqueous nasal spray and levocabastine on inflammatory cells in nasal lavage and clinical activity during the pollen season in seasonal rhinitics , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[104]  J. Bousquet,et al.  Perennial rhinitis: An independent risk factor for asthma in nonatopic subjects: results from the European Community Respiratory Health Survey. , 1999, The Journal of allergy and clinical immunology.

[105]  G. Guyatt,et al.  Development and validation of the Mini Asthma Quality of Life Questionnaire. , 1999, The European respiratory journal.

[106]  A. Buist,et al.  Validation of a standardized version of the Asthma Quality of Life Questionnaire. , 1999, Chest.

[107]  S. Ridout,et al.  Nasal budesonide offers superior symptom relief in perennial allergic rhinitis in comparison to nasal azelastine. , 1998, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[108]  F. Hampel,et al.  A comparison of the efficacy of fluticasone propionate aqueous nasal spray and loratadine, alone and in combination, for the treatment of seasonal allergic rhinitis. , 1998, The Journal of family practice.

[109]  G. Settipane,et al.  Co-existence of asthma and allergic rhinitis: a 23-year follow-up study of college students. , 1998, Allergy and asthma proceedings.

[110]  M. Andersson,et al.  Effects of topical budesonide and levocabastine on nasal symptoms and plasma exudation responses in seasonal allergic rhinitis , 1998, Allergy.

[111]  I. Jáuregui,et al.  [Investigation of the efficacy and tolerability of azelastine nasal spray versus ebastine tablets in patients with seasonal allergic rhinitis]. , 1998, Allergologia et immunopathologia.

[112]  M. de Waele,et al.  Effect of topical applications of budesonide and azelastine on nasal symptoms, eosinophil count and mediator release in atopic patients after nasal allergen challenge during the pollen season. , 1997, International archives of allergy and immunology.

[113]  J. Corren.  Allergic rhinitis and asthma: how important is the link? , 1997, The Journal of allergy and clinical immunology.

[114]  D. Malone,et al.  A cost of illness study of allergic rhinitis in the United States. , 1997, The Journal of allergy and clinical immunology.

[115]  G. Guyatt,et al.  Interpretation of rhinoconjunctivitis quality of life questionnaire data. , 1996, The Journal of allergy and clinical immunology.

[116]  S. Francom,et al.  Spectrum of Seasonal Allergic Rhinitis Symptom Relief with Topical Corticoid and Oral Antihistamine Given Singly or in Combination , 1996 .

[117]  William H. Yang,et al.  Faster onset of action with topical levocabastine than with oral cetirizine , 1995, Mediators of inflammation.

[118]  R. Lloyd,et al.  Evaluation of Fluticasone Propionate Aqueous Nasal Spray Taken Alone and in Combination with Cetirizine in the Prophylactic Treatment of Seasonal Allergic Rhinitis , 1994 .

[119]  P. McMenamin.  Costs of hay fever in the United States in 1990. , 1994, Annals of allergy.

[120]  D. Passali,et al.  A Comparison of Azelastine Nasal Spray and Cetirizine Tablets in the Treatment of Allergic Rhinitis , 1994, The Journal of international medical research.

[121]  G H Guyatt,et al.  Determining a minimal important change in a disease-specific Quality of Life Questionnaire. , 1994, Journal of clinical epidemiology.

[122]  R. Gambardella.  A Comparison of the Efficacy of Azelastine Nasal Spray and Loratidine Tablets in the Treatment of Seasonal Allergic Rhinitis , 1993, The Journal of international medical research.

[123]  P. Dorow,et al.  Efficacy and tolerability of azelastine nasal spray in patients with allergic rhinitis compared to placebo and budesonide. , 1993, Arzneimittel-Forschung.

[124]  H. Gastpar,et al.  Intranasal treatment of perennial allergic rhinitis. Comparison of azelastine nasal spray and budesonide nasal aerosol. , 1993, Arzneimittel-Forschung.

[125]  V. Lund,et al.  The effect of intranasal azelastine and beclomethasone on the symptoms and signs of nasal allergy in patients with perennial allergic rhinitis. , 1993, Rhinology.

[126]  P. Turkeltaub,et al.  The association of individual allergen reactivity with respiratory disease in a national sample: data from the second National Health and Nutrition Examination Survey, 1976-80 (NHANES II). , 1992, The Journal of allergy and clinical immunology.

[127]  C. Irvin,et al.  Nasal beclomethasone prevents the seasonal increase in bronchial responsiveness in patients with allergic rhinitis and asthma. , 1992, The Journal of allergy and clinical immunology.

[128]  G. Guyatt,et al.  Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. , 1992, Thorax.

[129]  B. Sibbald,et al.  Epidemiology of seasonal and perennial rhinitis: clinical presentation and medical history. , 1991, Thorax.

[130]  M. George.  Unmet needs. , 1991, Nursing times.

[131]  M. Bende,et al.  Topical levocabastine, a selective H1 antagonist, in seasonal allergic rhinoconjunctivitis , 1987, Allergy.

[132]  D Dionne,et al.  [What is integrated care?]. , 1987, Nursing Quebec.

[133]  P. A. Pedersen,et al.  Asthma and Allergic Rhinitis in the Same Patients , 1983, Allergy.